Plain-English translation of NCT07651540 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is evaluating a tool called the SEARS (Sensory Ataxia Rating Scale) to see if it can reliably measure how severe sensory nerve damage is and how patients are doing over time. Sensory neuropathies are rare conditions where the nerves that carry touch and position sensation are damaged, often from autoimmune diseases, cancer-related causes, or toxins. Right now, doctors don't have a good way to consistently measure these patients' symptoms and treatment response, so this study aims to validate this specialized rating scale.
Many patients with sensory nerve damage have poor outcomes and significant disability, but doctors currently lack a proven tool designed specifically for this condition to measure how sick patients are or whether treatments are working. This study exists to fill that gap by testing whether the new rating scale can become a reliable standard for following these patients' health over time.
You likely qualify if…
You likely don't qualify if…
You will undergo clinical evaluations using the new rating scale to assess your sensory nerve function and symptoms. The study will involve standard nerve tests and clinical assessments that measure how your condition affects your daily activities and balance. Your participation helps doctors understand whether this new tool can accurately track sensory nerve damage and guide treatment decisions for patients like you.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
France